The DOI matches its Crossref record; 120 of the 120 references it cites were found in a registry or an index.
Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics
Open accessAbstract
Although initially described as an anti-tumor mediator, tumor necrosis factor-alpha (TNF) is generally considered as the master pro-inflammatory cytokine. It plays a crucial role in the pathogenesis of inflammatory diseases, such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), ankylosing spondylitis (AS), and psoriasis. Consequently, anti-TNF therapy has become mainstay treatment for autoimmune diseases. Historically, anti-inflammatory agents were developed before the identification of TNF. Salicylates, the active components of Willow Spp., were identified in the mid-19th century for the alleviation of pain, fever, and inflammatory responses. Study of this naturally occurring compound led to the discovery of aspirin, which was followed by the development of non-steroidal anti-inflammatory drugs (NSAIDs) due to the chemical advances in the 19th-20th centuries. Initially, the most of NSAIDs were organic acid, but the non-acidic compounds were also identified as NSAIDs. Although effective in the treatment of inflammatory diseases, NSAIDs have some undesirable and adverse effect, such as ulcers, kidney injury and bleeding in the gastrointestinal tract. In the past two decades, anti-TNF biologics were developed. Drugs belong to this class include soluble TNF receptor 2 fusion protein and anti-TNF antibodies. The introduction of anti-TNF therapeutics has revolutionized the management of autoimmune diseases, such as RA, psoriatic arthritis (PsA), plaque psoriasis (PP), AS, CD and ulcerative colitis (UC). Nevertheless, up to 40% of patients have no response to anti-TNF treatment. Furthermore, this treatment is associated with some adverse effects such as increased risk of infection, and even triggered the de novo development of autoimmune diseases. Such harmful effect of anti-TNF treatment is likely caused by the global inhibition of TNF biological functions. Therefore, specific inhibition of TNF receptor (TNFR1 or TNFR2) may represent a safer and more effective treatment, as proposed by some recent studies. In this review article, the historical development of anti-inflammatory drugs after World War II as briefly described above will be reviewed and analyzed. The future trend in the development of novel TNF receptor-targeting therapeutics will be discussed in the context of latest progress in the research of TNF biology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: The treatment of rheumatoid arthritis
Simon, L. S. (2004) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2004.04.005 · Cited by 19
RetractedChen, X., Xiu, M., Xing, J., Yu, S., Min, D., & Guo, F. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479439 · Cited by 5,742
Self-citationAn endotoxin-induced serum factor that causes necrosis of tumors
Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., & Williamson, B. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.9.3666 · Cited by 4,532
A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells
Black, R. A., Rauch, C. T., Kozlosky, C. J., Peschon, J. J., Slack, J. L., Wolfson, M. F., Castner, B. J., Stocking, K. L., Reddy, P., Srinivasan, S., et al. (1997) · Nature · doi:10.1038/385729a0 · Cited by 3,149
Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
Rhen, T., & Cidlowski, J. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050541 · Cited by 3,149
Signalling pathways of the TNF superfamily: a double-edged sword
Aggarwal, B. B. (2003) · Nature Reviews Immunology · doi:10.1038/nri1184 · Cited by 2,793
ROLE OF CYTOKINES IN RHEUMATOID ARTHRITIS
Feldmann, M., Brennan, F. M., & Maini, R. N. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.397 · Cited by 2,514
Bongartz, T., Sutton, A. J., Sweeting, M. J., Buchan, I., Matteson, E. L., & Montori, V. (2006) · JAMA · doi:10.1001/jama.295.19.2275 · Cited by 2,468
Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition
Simmons, D. L., Botting, R. M., & Hla, T. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.3.3 · Cited by 1,693
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G., & Tak, P. P. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.10.001 · Cited by 1,628
Anti-inflammatory Actions of Glucocorticoids: Molecular Mechanisms
Barnes, P. J. (1998) · Clinical Science · doi:10.1042/cs0940557 · Cited by 1,591
Etanercept Therapy in Rheumatoid Arthritis: A Randomized, Controlled Trial
Moreland, L. W., Schiff, M. H., Baumgartner, S. W., Tindall, E. A., Fleischmann, R. M., Bulpitt, K. J., Weaver, A. L., Keystone, E. C., Furst, D. E., Mease, P. J., et al. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00004 · Cited by 1,379
Grell, M., Douni, E., Wajant, H., Löhden, M., Clauss, M., Maxeiner, B., Georgopoulos, S., Lesslauer, W., Kollias, G., Pfizenmaier, K., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90192-2 · Cited by 1,325
Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition
Genovese, M. C., Becker, J.-C., Schiff, M., Luggen, M., Sherrer, Y., Kremer, J., Birbara, C., Box, J., Natarajan, K., Nuamah, I., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050524 · Cited by 1,241
Hench, P. S., Kendall, E. C., Slocumb, C. H., & Polley, H. F. (1949) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00526-3 · Cited by 1,179
Fang, F. C. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119473 · Cited by 1,149
Anti-Inflammatory Therapy in Chronic Disease: Challenges and Opportunities
Tabas, I., & Glass, C. K. (2013) · Science · doi:10.1126/science.1230720 · Cited by 1,093
Boers, M., Verhoeven, A. C., Markusse, H. M., van de Laar, M. A., Westhovens, R., van Denderen, J. C., van Zeben, D., Dijkmans, B. A., Peeters, A. J., Jacobs, P., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(97)01300-7 · Cited by 1,073
Grosser, T. (2005) · Journal of Clinical Investigation · doi:10.1172/jci27291 · Cited by 1,027
Emery, P., Breedveld, F. C., Hall, S., Durez, P., Chang, D. J., Robertson, D., Singh, A., Pedersen, R. D., Koenig, A. S., & Freundlich, B. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61000-4 · Cited by 821
Antman, E. M., Bennett, J. S., Daugherty, A., Furberg, C., Roberts, H., & Taubert, K. A. (2007) · Circulation · doi:10.1161/circulationaha.106.181424 · Cited by 804
Two tumour necrosis factor receptors: structure and function
Vandenabeele, P., Declercq, W., Beyaert, R., & Fiers, W. (1995) · Trends in Cell Biology · doi:10.1016/s0962-8924(00)89088-1 · Cited by 799
Sulfasalazine: A potent and specific inhibitor of nuclear factor kappa B
Wahl, C., Liptay, S., Adler, G., & Schmid, R. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci992 · Cited by 742
Cooper, G. S., Bynum, M. L. K., & Somers, E. C. (2009) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.09.008 · Cited by 736
Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management
Roda, G., Jharap, B., Neeraj, N., & Colombel, J.-F. (2016) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2015.63 · Cited by 723
CONTRIBUTION TO THE KNOWLEDGE OF SARCOMA
COLEY, W. B. (1891) · Annals of Surgery · doi:10.1097/00000658-189112000-00015 · Cited by 715
COX-1 and COX-2 tissue expression: implications and predictions.
Crofford, L. J. (1997) · PubMed · Cited by 675
Yoo, D. H., Hrycaj, P., Miranda, P., Ramiterre, E., Piotrowski, M., Shevchuk, S., Kovalenko, V., Prodanovic, N., Abello-Banfi, M., Gutierrez-Ureña, S., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-203090 · Cited by 654
O’Dell, J. R., Haire, C. E., Erikson, N., Drymalski, W., PALMER, W. R., Eckhoff, P. J., Garwood, V., Maloley, P. A., Klassen, L. W., Wees, S. J., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605163342002 · Cited by 654
van de Putte, L. B. A., Atkins, C., Malaise, M., Sany, J., Russell, A. S., van Riel, P. L. C. M., Settas, L., Bijlsma, J. W., Todesco, S., Dougados, M., et al. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.013052 · Cited by 617
Population‐based assessment of adverse events associated with long‐term glucocorticoid use
Curtis, J. R., Westfall, A. O., Allison, J., Bijlsma, J. W., Freeman, A., George, V., Kovac, S. H., Spettell, C. M., & Saag, K. G. (2006) · Arthritis Care & Research · doi:10.1002/art.21984 · Cited by 595
Anti-TNF therapy: past, present and future
Monaco, C., Nanchahal, J., Taylor, P., & Feldmann, M. (2015) · International Immunology · doi:10.1093/intimm/dxu102 · Cited by 581
Schreiber, S., Rutgeerts, P., Fedorak, R. N., Khaliq–Kareemi, M., Kamm, M. A., Boivin, M., Bernstein, C. N., Staun, M., Thomsen, O. Ø., & Innes, A. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.06.064 · Cited by 580
Anti-TNF-α therapies: the next generation
Palladino, M. A., Bahjat, F. R., Theodorakis, E. A., & Moldawer, L. L. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1175 · Cited by 576
Keystone, E., Heijde, D. V. D., Mason, D., Landewé, R., Vollenhoven, R. V., Combe, B., Emery, P., Strand, V., Mease, P., Desai, C., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23964 · Cited by 576
Chen, X., Bäumel, M., Männel, D. N., Howard, O. M. Z., & Oppenheim, J. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.1.154 · Cited by 548
Self-citationCOX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease
Ray, W. A., Stein, C. M., Daugherty, J. R., Hall, K., Arbogast, P. G., & Griffin, M. R. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11131-7 · Cited by 503
Inflammatory networks underlying colorectal cancer
Lasry, A., Zinger, A., & Ben-Neriah, Y. (2016) · Nature Immunology · doi:10.1038/ni.3384 · Cited by 489
Anti-Inflammatory Drugs in the 21st Century
Rainsford, K. D. (2007) · Subcellular Biochemistry · doi:10.1007/1-4020-5688-5_1 · Cited by 463
TNF receptor 2 pathway: drug target for autoimmune diseases
Faustman, D., & Davis, M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3030 · Cited by 446
Mechanism of Action for Leflunomide in Rheumatoid Arthritis
Fox, R. I., Herrmann, M. L., Frangou, C. G., Wahl, G. M., Morris, R. E., Strand, V., & Kirschbaum, B. J. (1999) · Clinical Immunology · doi:10.1006/clim.1999.4777 · Cited by 420
Biological functions of tumor necrosis factor cytokines and their receptors
Pfeffer, K. (2003) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(03)00022-4 · Cited by 415
Fleischmann, R. M., Schechtman, J., Bennett, R., Handel, M. L., Burmester, G., Tesser, J., Modafferi, D., Poulakos, J., & Sun, G. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10870 · Cited by 392
Methotrexate in Rheumatoid Arthritis
(1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-2-418 · Cited by 345
Chen, X., Subleski, J. J., Kopf, H., Howard, O. M. Z., Männel, D. N., & Oppenheim, J. J. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.10.6467 · Cited by 335
Self-citationVisser, K., & van der Heijde, D. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092668 · Cited by 328
Robinson, W. H., Genovese, M. C., & Moreland, L. W. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200109)44:9<1977::aid-art345>3.0.co;2-6 · Cited by 310
Minozzi, S., Bonovas, S., Lytras, T., Pecoraro, V., González-Lorenzo, M., Bastiampillai, A. J., Gabrielli, E. M., Lonati, A. C., Moja, L., Cinquini, M., et al. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1240783 · Cited by 308
Jang, C.-H., Choi, J.-H., Byun, M.-S., & Jue, D.-M. (2006) · Rheumatology · doi:10.1093/rheumatology/kei282 · Cited by 305
Renal Toxicity of the Nonsteroidal Anti-Inflammatory Drugs
Murray, M. D., & Brater, D. C. (1993) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.33.040193.002251 · Cited by 294
Chen, X., Wu, X., Zhou, Q., Howard, O. M. Z., Netea, M. G., & Oppenheim, J. J. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202659 · Cited by 293
Self-citationSharp, J. T., Strand, V., Leung, H., Hurley, F., & Loew-Friedrich, I. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200003)43:3<495::aid-anr4>3.0.co;2-u · Cited by 278
Sandborn, W. J., Hanauer, S., Loftus, E. V., Tremaine, W. J., Kane, S., Cohen, R., Hanson, K., Johnson, T., Schmitt, D., & Jeche, R. (2004) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.40462.x · Cited by 276
Cytokines in Autoimmunity: Role in Induction, Regulation, and Treatment
Moudgil, K. D., & Choubey, D. (2011) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2011.0065 · Cited by 265
Leflunomide or Methotrexate for Juvenile Rheumatoid Arthritis
Silverman, E., Mouy, R., Spiegel, L., Jung, L. K., Saurenmann, R. K., Lahdenne, P., Horneff, G., Calvo, I., Szer, I. S., Simpson, K., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041810 · Cited by 260
Shealy, D. J., Cai, A., Staquet, K., Baker, A., Lacy, E. R., Johns, L., Vafa, O., Gunn, G., Tam, S., Sague, S., et al. (2010) · mAbs · doi:10.4161/mabs.12304 · Cited by 243
van Vollenhoven, R. F., Geborek, P., Forslind, K., Albertsson, K., Ernestam, S., Petersson, I. F., Chatzidionysiou, K., & Bratt, J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60027-0 · Cited by 228
Chen, X., Oppenheim, J. J., Winkler‐Pickett, R. T., Ortaldo, J. R., & Howard, O. M. Z. (2006) · European Journal of Immunology · doi:10.1002/eji.200635873 · Cited by 219
Self-citationChoy, E. H. S. (2002) · Rheumatology · doi:10.1093/rheumatology/41.10.1133 · Cited by 213
Chen, X., Subleski, J. J., Hamano, R., Howard, O. M. Z., Wiltrout, R. H., & Oppenheim, J. J. (2010) · European Journal of Immunology · doi:10.1002/eji.200940022 · Cited by 207
Self-citationDifferential response of murine CD4+CD25+ and CD4+CD25– T cells to dexamethasone‐induced cell death
Chen, X., Murakami, T., Oppenheim, J. J., & Howard, O. M. Z. (2004) · European Journal of Immunology · doi:10.1002/eji.200324506 · Cited by 195
Self-citationThe changing landscape of biosimilars in rheumatology
Dörner, T., Strand, V., Cornes, P., Gonçalves, J., Gulácsi, L., Kay, J., Kvien, T. K., Smolen, J., Tanaka, Y., & Burmester, G. R. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209166 · Cited by 194
Zhou, H., Jang, H., Fleischmann, R. M., Bouman‐Thio, E., Xu, Z., Marini, J. C., Pendley, C., Jiao, Q., Shankar, G., Marciniak, S. J., et al. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006298188 · Cited by 191
Nguyen, D. X., & Ehrenstein, M. R. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20151255 · Cited by 184
Autoimmune thyroid disease in systemic lupus erythematosus
Pyne, D., & Isenberg, D. A. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.1.70 · Cited by 173
Homogeneous Expansion of Human T-Regulatory Cells Via Tumor Necrosis Factor Receptor 2
Okubo, Y., Mera, T., Wang, L., & Faustman, D. L. (2013) · Scientific Reports · doi:10.1038/srep03153 · Cited by 170
Side effects of anti-TNF therapy: current knowledge.
Antoni, C., & Braun, J. (2003) · PubMed · Cited by 163
Autoimmunity and Anti-TNF-α Agents
ATZENI, F., TURIEL, M., CAPSONI, F., DORIA, A., MERONI, P., & SARZI-PUTTINI, P. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1361.100 · Cited by 160
Rau, R. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.suppl_2.ii70 · Cited by 159
Treatment with gamma‐interferon triggers the onset of collagen arthritis in mice
Mauritz, N. J., Holmdahl, R., Jonsson, R., van der Meide, P. H., Scheynius, A., & Klareskog, L. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780311012 · Cited by 154
Shelton, E., Laharie, D., Scott, F. I., Mamtani, R., Lewis, J. D., Colombel, J., & Ananthakrishnan, A. N. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.03.037 · Cited by 152
Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases
Willrich, M. A. V., Murray, D. L., & Snyder, M. R. (2014) · Translational research · doi:10.1016/j.trsl.2014.09.006 · Cited by 148
Campa, M., Mansouri, B., Warren, R. B., & Menter, A. (2015) · Dermatology and Therapy · doi:10.1007/s13555-015-0092-3 · Cited by 144
Current Immunotherapy in Rheumatoid Arthritis
Meier, F. M. P., Frerix, M., Hermann, W., & Müller‐Ladner, U. (2013) · Immunotherapy · doi:10.2217/imt.13.94 · Cited by 135
Pasut, G. (2014) · BioDrugs · doi:10.1007/s40259-013-0064-z · Cited by 126
A Critical Review of the Effects of Hydroxychloroquine and Chloroquine on the Eye
Costedoat-Chalumeau, N., Dunogué, B., Leroux, G., Morel, N., Jallouli, M., Guern, V. L., Pietté, J. C., Brézin, A. P., Melles, R. B., & Marmor, M. F. (2015) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-015-8469-8 · Cited by 126
Collagen-Induced Arthritis as an Animal Model for Rheumatoid Arthritis: Focus on Interferon-γ
Schurgers, E., Billiau, A., & Matthys, P. (2011) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2011.0056 · Cited by 117
The fight against rheumatism: from willow bark to COX-1 sparing drugs.
Vane, J. R. (2000) · PubMed · Cited by 115
McCann, F. E., Perocheau, D. P. B., Ruspi, G., Blazek, K. D., Davies, M. L., Feldmann, M., Dean, J. L. E., Stoop, A. A., & Williams, R. O. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38755 · Cited by 110
Methotrexate in rheumatoid arthritis
Chan, E. S. L., Fernández, P., & Cronstein, B. N. (2006) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.3.1.27 · Cited by 110
Guerra, I., Algaba, A., Pérez-Calle, J. L., Chaparro, M., Marín‐Jiménez, I., García-Castellanos, R., González‐Lama, Y., López–Sanromán, A., Manceñido, N., Martínez-Montiel, P., et al. (2011) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2011.10.007 · Cited by 106
Exogenous and endogenous glucocorticoids in rheumatic diseases
Buttgereit, F., Burmester, G., Straub, R. H., Seibel, M. J., & Zhou, H. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30070 · Cited by 105
Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.
Dajani, E. Z., & Islam, K. (2008) · PubMed · Cited by 101
Gamma-interferon: the match that lights the fire?
Billiau, A. (1988) · Immunology Today · doi:10.1016/0167-5699(88)91256-x · Cited by 100
Chen, X., & Oppenheim, J. J. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.04.025 · Cited by 99
Self-citationSuppressive activity of human regulatory T cells is maintained in the presence of TNF
Zaragoza, B., Chen, X., Oppenheim, J. J., Baeyens, A., Grégoire, S., Chader, D., Gorochov, G., Miyara, M., & Salomon, B. L. (2016) · Nature Medicine · doi:10.1038/nm.4019 · Cited by 97
Self-citationAssociation of the TNF-α G-308A polymorphism with TNF-inhibitor response in sarcoidosis
Wijnen, P. A. H. M., Cremers, J. P., Nelemans, P. J., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00169413 · Cited by 95
Randomized, double-blind trial of anti-interferon-?antibodies in rheumatoid arthritis
Sigidin, G. V. L. Y. A. (2001) · Scandinavian Journal of Rheumatology · doi:10.1080/030097401316909530 · Cited by 94
Anti-arthritic agents: Progress and potential
Laev, S. S., & Salakhutdinov, N. F. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.05.010 · Cited by 90
Adalimumab in the Treatment of Immune-Mediated Diseases
Lapadula, G., Marchesoni, A., Armuzzi, A., Blandizzi, C., Caporali, R. F., Chimenti, S., Cimaz, R., Cimino, L., Gionchetti, P., Girolomoni, G., et al. (2014) · International Journal of Immunopathology and Pharmacology · doi:10.1177/03946320140270s103 · Cited by 88
Methotrexate for the treatment of rheumatoid arthritis in the biologic era: Still an “anchor” drug?
Favalli, E. G., Biggioggero, M., & Meroni, P. L. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.08.026 · Cited by 87
Lebwohl, M., Emer, J. J., & Koutruba, N. (2010) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s5599 · Cited by 84
Anti-TNF-α Antibody Therapies in Autoimmune Diseases
Chatzantoni, K., & Mouzaki, Α. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606778194217 · Cited by 83
Minozzi, S., Bonovas, S., Lytras, T., Pecoraro, V. L., González‐Lorenzo, M., Bastiampillai, A. J., Gabrielli, E., Lonati, A. C., Moja, L., Cinquini, M., et al. (2016) · Expert Opinion on Drug Safety · Cited by 75
Etanercept: efficacy and safety for approved indications
Kerensky, T. A., Gottlieb, A. B., Yaniv, S., & Au, S.-C. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.633509 · Cited by 71
Sol, V. V., Díaz‐Muñoz, M. D., & Fresno, M. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.0905529 · Cited by 68
Anti‐Tumour Necrosis Factor‐α Therapy in Heart Failure: Future Directions
Balakumar, P., & Singh, M. (2006) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2006.pto_508.x · Cited by 68
Safety of Biologic Therapy in Rheumatoid Arthritis and Other Autoimmune Diseases: Focus on Rituximab
Fleischmann, R. (2008) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2008.01.001 · Cited by 65
Kinetics and Dynamics of Prednisolone*
Frey, F. J. (1987) · Endocrine Reviews · doi:10.1210/edrv-8-4-453 · Cited by 64
Review of tocilizumab in the treatment of rheumatoid arthritis
Okuda, Y. (2008) · Biologics : Targets & Therapy · doi:10.2147/btt.s1828 · Cited by 63
Systemic methotrexate for the treatment of psoriasis
Yélamos, O., & Puig, L. (2015) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2015.1026894 · Cited by 61
The discovery and early use of cortisone
Glyn, J. H. (1998) · Journal of the Royal Society of Medicine · doi:10.1177/014107689809101004 · Cited by 57
Shibata, H., Yoshioka, Y., Abe, Y., Ohkawa, A., Nomura, T., Minowa, K., Mukai, Y., Nakagawa, S., Taniai, M., Ohta, T., et al. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.08.041 · Cited by 54
Fifty Years of Experience with Cortisone Therapy in the Study and Treatment of Rheumatoid Arthritis
Neeck, G. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04199.x · Cited by 53
Public health awareness of autoimmune diseases after the death of a celebrity
Bragazzi, N. L., Watad, ., Brigo, F., Adawi, M., Amital, H., & Shoenfeld, Y. (2016) · Clinical Rheumatology · doi:10.1007/s10067-016-3513-5 · Cited by 53
Khanapure, S. P., Garvey, D. S., Young, D. V., Ezawa, M., Earl, R. A., Gaston, R. D., Fang, X., Murty, M. G., Martino, A. M., Shumway, M. J., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030268b · Cited by 52
Chen, X., Willette‐Brown, J., Wu, X., Hu, Y. N., Howard, O. M. Z., Hu, Y., & Oppenheim, J. J. (2014) · The FASEB Journal · doi:10.1096/fj.14-259564 · Cited by 52
Self-citationWhat do we know about the safety of corticosteroids in rheumatoid arthritis?
Ethgen, O., Esteves, F. D. L., Bruyère, O., & Reginster, J. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.818531 · Cited by 51
The Biological and Clinical Activity of Anti-Malarial Drugs In Autoimmune Disorders
Taherian, E., Rao, A., Malemud, C. J., & Askari, A. (2013) · Current Rheumatology Reviews · doi:10.2174/1573397111309010010 · Cited by 50
TNFR2 expression by CD4 effector T cells is required to induce full-fledged experimental colitis
Chen, X., Nie, Y., Xiao, H., Bian, Z., Scarzello, A. J., Song, N., Trivett, A. L., Yang, D., & Oppenheim, J. J. (2016) · Scientific Reports · doi:10.1038/srep32834 · Cited by 50
Self-citationBiologic agents in rheumatology: unmet issues after 200 trials and $200 billion sales
Ioannidis, J. P. A., Karassa, F. B., Druyts, E., Thorlund, K., & Mills, E. J. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.134 · Cited by 48
Nathan, D. M., Iser, J. H., & Gibson, P. R. (2007) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.05006.x · Cited by 47
A Clinical and Economic Review of Disease-Modifying Antirheumatic Drugs
Gabriel, S. E., Coyle, D., & Moreland, L. W. (2001) · PharmacoEconomics · doi:10.2165/00019053-200119070-00002 · Cited by 44
Coxibs, non‐steroidal anti‐inflammatory drugs and cardiovascular risk
Hermann, M., & Ruschitzka, F. T. (2006) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2006.01056.x · Cited by 42
Ellingsen, T., Hornung, N., Moller, B. K., Poulsen, J. H., & Stengaard‐Pedersen, K. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.054056 · Cited by 42
The biosimilar road in inflammatory bowel disease: The right way?
Fiorino, G., & Danese, S. (2014) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2014.04.006 · Cited by 29
Govindaraj, C., Scalzo‐Inguanti, K., Scholzen, A., Li, S., & Plebanski, M. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00233 · Cited by 28
Ellis, J. S., & Braley‐Mullen, H. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6020013 · Cited by 25
Tumor Necrosis Factor and the consequences of its ablation in vivo
Efimov, G. A., Kruglov, A., Tillib, S. V., Kuprash, D. V., & Nedospasov, S. A. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.01.007 · Cited by 22
Paradoxical effects of targeting TNF signalling in the treatment of autoimmunity
Chen, X., & Oppenheim, J. J. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.145 · Cited by 21
Self-citation
Cited by
Sun, L., Su, Y., Jiao, A., Wang, X., & Zhang, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01471-y · Cited by 1,014
Wang, J., Jiang, M., Chen, X., & Montaner, L. J. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.3covr0520-272r · Cited by 741
Self-citationGinwala, R., Bhavsar, R., Chigbu, D. G. I., Jain, P., & Khan, Z. K. (2019) · Antioxidants · doi:10.3390/antiox8020035 · Cited by 588
Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development
Ovacik, M., & Lin, K. (2018) · Clinical and Translational Science · doi:10.1111/cts.12567 · Cited by 299
Crimean–Congo haemorrhagic fever virus
Hawman, D. W., & Feldmann, H. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00871-9 · Cited by 287
Metadata
- Authors
- Li, P., Zheng, Y., & Chen, X.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2017-07-12
- Volume
- 8
- Pages
- 460-460
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2734398306
- Cited by
- 346
- References
- 120
- FWCI
- 21.81
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.